Obese Patients With Nonalcoholic Fatty Liver Disease Have an Increase in Soluble Plasma CD163 and a Concurrent Decrease in Hepatic Expression of CD163

Skytthe, Maria Kløjgaard; Pedersen, Felix Boel; Wernberg, Charlotte; Chandran, Vineesh Indira; Krag, Aleksander; Caterino, Tina Di; Mandacaru, Samuel Coelho; Blagoev, Blagoy; Lauridsen, Mette Munk; Detlefsen, Sönke; Graversen, Jonas Heilskov; Moestrup, Søren K.

doi:10.1016/j.gastha.2023.03.006

Cited by 1 publication

(2 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5h,i). We also found an inverse relationship for CD163 where CD163 is downregulated in liver but upregulated in blood plasma, corroborating previous findings 43 .…”

Section: Identification Of Masld-associated Proteins In Blood Plasmasupporting

confidence: 92%

See 1 more Smart Citation

Deep Proteome Profiling of Metabolic Dysfunction-Associated Steatotic Liver Disease

Boel,

Akimov,

Teuchler

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects roughly 1 in 3 adults and is a leading cause of liver transplants and liver related mortality. A deeper understanding of disease pathogenesis is essential to assist in developing blood-based biomarkers. Here, we use data-independent acquisition mass spectrometry to assess disease-state associated protein profiles in human liver, blood plasma, and white adipose tissue (WAT). In liver, we find that MASLD is associated with an increased abundance of proteins involved in immune response and extracellular matrix (ECM) and a decrease in proteins involved in metabolism. Cell type deconvolution of the proteome indicate liver endothelial and hepatic stellate cells as main source of the ECM rearrangements, and hepatocytes as the major contributor to the changes in liver metabolism. In the blood, profiles of several MASLD-associated proteins that correlate with their expression in WAT rather than liver yet could serve as suitable liver disease predictors in a multi-protein panel marker. Moreover, our proteomics-based logistic regression models consistently outperform existing methods for predicting MASLD and liver fibrosis from human blood samples.

show abstract

“…5h,i). We also found an inverse relationship for CD163 where CD163 is downregulated in liver but upregulated in blood plasma, corroborating previous findings 43 .…”

Section: Identification Of Masld-associated Proteins In Blood Plasmasupporting

confidence: 92%

“…The copyright holder for this preprint this version posted May 24, 2024. ; https://doi.org/10.1101/2024.05.24.595658 doi: bioRxiv preprint CD163 where CD163 is downregulated in liver but upregulated in blood plasma, corroborating previous findings 43 .…”

Section: Identification Of Masld-associated Proteins In Blood Plasmasupporting

confidence: 87%

Deep Proteome Profiling of Metabolic Dysfunction-Associated Steatotic Liver Disease

Boel,

Akimov,

Teuchler

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

Obese Patients With Nonalcoholic Fatty Liver Disease Have an Increase in Soluble Plasma CD163 and a Concurrent Decrease in Hepatic Expression of CD163

Cited by 1 publication

References 72 publications

Deep Proteome Profiling of Metabolic Dysfunction-Associated Steatotic Liver Disease

Deep Proteome Profiling of Metabolic Dysfunction-Associated Steatotic Liver Disease

Contact Info

Product

Resources

About